Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2020

View Archived Issues

Atherosclerosis, AD meet at the myelin

p53 loss leads to immune evasion

Karus Therapeutics initiates phase II study of KA-2507 in biliary tract cancer

Enrollment open in phase II study of MSTT-1041A or UTTR-1147A in COVID-19 pneumonia

Clinical data for novel non-D2-receptor-binding compound in patients with schizophrenia

DNA-encoded immunotherapies show efficacy in models of N. gonorrhoeae infection

First-in-human characterization of RPT-193

IRAK-2 is a therapeutic target in atopic dermatitis and psoriasis

AiCuris discovers HBV caspid assembly inhibitors

New SSAO inhibitors identified at Boehringer Ingelheim

Esteve patents voltage-dependent calcium channel subunit alpha2/delta-1 ligands

Merck & Co. identifies new LRRK2 inhibitors

New TYK2 inhibitors disclosed by Bristol-Myers Squibb

Germline ApoE variants affect melanoma trajectory

PEG10 found behind pathogenic mechanisms of mycosis fungoides

Phase III trial of efgartigimod in generalized myasthenia gravis meets primary endpoint

Chi-Med and BeiGene to study surufatinib and fruquintinib with tislelizumab for solid tumors

Synairgen's phase II trial begins dosing SNG-001 in home setting to treat COVID-19

Novartis begins phase II study of DFV-890 for COVID-19 pneumonia

Glenmark to begin phase III study of favipiravir with umifenovir in moderate COVID-19

Tavotek and Genmab partner to develop antibody for autoimmune and inflammatory conditions

Levels of cytokine LIGHT correlate with disease severity and mortality in COVID-19 ARDS study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...